The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Status and phase
Completed
Phase 4
Conditions
Conduct Disorder
Treatments
Drug: Oxcarbazepine
Details and patient eligibility
About
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.
Enrollment
50 patients
Sex
All
Ages
6 to 16 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
- Score >8 on the Impulsivity Rating Scale
Exclusion criteria
- Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
- Treatment with antiepileptic medications
Other protocol-defined inclusion/exclusion criteria may apply.
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Crossover Assignment
Masking
Double Blind
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems